Geoffrey Parker - Perrigo Company Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 25px;;'>PRG</div>
PRGO -- USA Stock  

Last Earning Anouncement Date: December 31, 2015  

  Director
Mr. Geoffrey M. Parker is the Independent Director of the Company. Since April 2017, Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of Genomic Health and ChemoCentryx since June 2016, and December 2009, respectively. Mr. Parker served on the board of directors of Sunesis Pharmaceuticals from March 2016 until December 2017.
Age: 53  Director Since 2016      
353 1 709 4000  http://www.perrigo.com
Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals fromSeptember 2010to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. He holds an A.B. degree in Economics and Engineering Science fromDartmouth Collegeand an MBA from the Stanford Graduate School of Business.

Geoffrey Parker Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Yingqi XiaOrigin Agritech Limited
2010
J MoreauDr Reddys Laboratories Ltd
2007
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Ashok GangulyDr Reddys Laboratories Ltd
2009
Michael BrownRegeneron Pharmaceuticals
1991
Gregory NordenZoetis
2013
Fei WangOrigin Agritech Limited
2019
Prasad MenonDr Reddys Laboratories Ltd
2019
Alfred GilmanRegeneron Pharmaceuticals
1990
Shikha SharmaDr Reddys Laboratories Ltd
2019
William YoungVertex Pharmaceuticals Incorpor
2014
Anupam PuriDr Reddys Laboratories Ltd
2002
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Michael TrimbleOrigin Agritech Limited
2006
Bharat DoshiDr Reddys Laboratories Ltd
2016
Leo PuriDr Reddys Laboratories Ltd
2018
Larry CordellOrigin Agritech Limited
2012
George SingRegeneron Pharmaceuticals
1988
Paul BisaroZoetis
2015
William DoyleZoetis
2015

Entity Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Current Sentiment - PRGO

Perrigo Company Investor Sentiment

Most of Macroaxis users are at this time bullish on Perrigo Company Plc. What is your perspective on investing in Perrigo Company Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

USRT   
Purchased few shares of
a day ago
Traded for 55.68
IJR   
Purchased few shares of
a day ago
Traded for 85.37
IJH   
Purchased one share of
a day ago
Traded for 209.15
IVV   
Purchased one share of
a day ago
Traded for 333.5
IDEV   
Purchased few shares of
a day ago
Traded for 59.01
Please also check Your Equity Center. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.